GSK Slams Mylan's Bid For $3.1M Interest In Paxil Row
GlaxoSmithKline LLC on Monday slammed Mylan Inc.'s bid for $3.1 million in prejudgment interest stemming from the $106.7 million verdict Mylan won after a jury found that GSK breached an exclusive...To view the full article, register now.
Already a subscriber? Click here to view full article